Drugs / FPV-Brachyury
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03349983 | Jan 2018 → Jun 2020 | — | Bavarian Nordic | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03493945 | May 2018 → Oct 2024 | castration-resistant prostate carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05445882 | Apr 2024 | castration-resistant prostate carcinoma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 2 | NCT03595228 | Oct 2018 → Dec 2021 | chordoma | Bavarian Nordic | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FPV-Brachyury | “FPV-Brachyury injection will be given on day 28, followed by radiation on days 42 through approximately day 70.” NCT03595228 ↗3“BN-Brachyury collectively refers to the priming doses (MVA-BN-Brachyury) and the boost doses (FPV-Brachyury).” NCT05445882 ↗ |
| Modality | Vaccine | “MVA-BN-Brachyury priming and FPV-Brachyury boost vaccines” NCT03349983 ↗ |
| Route | Subcutaneous | “FPV-brachyury s.c., 1 × 109 IU” PMID 31876334 ↗ Dec 2019 |